Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis. 2003

Yossi Gilgun-Sherki, and Hana Panet, and Vered Holdengreber, and Ronit Mosberg-Galili, and Daniel Offen
Department of Neurology and Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus, The Sackler School of Medicine, Tel Aviv University, Petah Tikva 49100, Israel.

Glatiramer acetate (GA) is efficacious in reducing demyelinating-associated exacerbations in patients with relapsing-remitting multiple sclerosis (RRMS) and in several experimental autoimmune encephalomyelitis (EAE) models. Here we report that GA reduced the clinical and pathological signs of mice in chronic EAE induced by myelin oligodendrocyte glycoprotein (MOG). GA-treated mice demonstrated only mild focal inflammation, and less demyelination, compared with controls. Moreover, we also found minimal axonal disruption, as assessed by silver staining, antibodies against amyloid precursor protein (APP) and non-phosphorylated neurofilaments (SMI-32), in the GA-treated group. In conclusion, our study demonstrated for the first time that axonal damage is reduced following GA treatment in C57/bl mice with chronic MOG-induced EAE.

UI MeSH Term Description Entries
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004681 Encephalomyelitis, Autoimmune, Experimental An experimental animal model for central nervous system demyelinating disease. Inoculation with a white matter emulsion combined with FREUND'S ADJUVANT, myelin basic protein, or purified central myelin triggers a T cell-mediated immune response directed towards central myelin. The pathologic features are similar to MULTIPLE SCLEROSIS, including perivascular and periventricular foci of inflammation and demyelination. Subpial demyelination underlying meningeal infiltrations also occurs, which is also a feature of ENCEPHALOMYELITIS, ACUTE DISSEMINATED. Passive immunization with T-cells from an afflicted animal to a normal animal also induces this condition. (From Immunol Res 1998;17(1-2):217-27; Raine CS, Textbook of Neuropathology, 2nd ed, p604-5) Autoimmune Encephalomyelitis, Experimental,Encephalomyelitis, Allergic,Encephalomyelitis, Experimental Autoimmune,Allergic Encephalomyelitis,Allergic Encephalomyelitis, Experimental,Autoimmune Experimental Encephalomyelitis,Experimental Allergic Encephalomyelitis,Experimental Autoimmune Encephalomyelitis,Encephalomyelitis, Autoimmune Experimental,Encephalomyelitis, Experimental Allergic,Experimental Allergic Encephalomyelitides,Experimental Encephalomyelitis, Autoimmune
D000068717 Glatiramer Acetate A random polymer of L-ALANINE, L-GLUTAMIC ACID, L-LYSINE, and L-TYROSINE that structurally resembles MYELIN BASIC PROTEIN. It is used in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS. Copaxone,Glatiramer,TV 5010,TV-5010,TV5010,5010, TV,Acetate, Glatiramer
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001369 Axons Nerve fibers that are capable of rapidly conducting impulses away from the neuron cell body. Axon
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Yossi Gilgun-Sherki, and Hana Panet, and Vered Holdengreber, and Ronit Mosberg-Galili, and Daniel Offen
October 2010, PloS one,
Yossi Gilgun-Sherki, and Hana Panet, and Vered Holdengreber, and Ronit Mosberg-Galili, and Daniel Offen
May 2009, Journal of neuroimmunology,
Yossi Gilgun-Sherki, and Hana Panet, and Vered Holdengreber, and Ronit Mosberg-Galili, and Daniel Offen
January 2010, Experimental neurology,
Yossi Gilgun-Sherki, and Hana Panet, and Vered Holdengreber, and Ronit Mosberg-Galili, and Daniel Offen
August 2008, Proceedings of the National Academy of Sciences of the United States of America,
Yossi Gilgun-Sherki, and Hana Panet, and Vered Holdengreber, and Ronit Mosberg-Galili, and Daniel Offen
March 2010, European journal of pharmacology,
Yossi Gilgun-Sherki, and Hana Panet, and Vered Holdengreber, and Ronit Mosberg-Galili, and Daniel Offen
October 2013, Neuropharmacology,
Yossi Gilgun-Sherki, and Hana Panet, and Vered Holdengreber, and Ronit Mosberg-Galili, and Daniel Offen
September 2010, Journal of neuroimmunology,
Yossi Gilgun-Sherki, and Hana Panet, and Vered Holdengreber, and Ronit Mosberg-Galili, and Daniel Offen
June 2013, Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology,
Yossi Gilgun-Sherki, and Hana Panet, and Vered Holdengreber, and Ronit Mosberg-Galili, and Daniel Offen
December 2004, Annals of the New York Academy of Sciences,
Yossi Gilgun-Sherki, and Hana Panet, and Vered Holdengreber, and Ronit Mosberg-Galili, and Daniel Offen
February 2010, Journal of neuroimmunology,
Copied contents to your clipboard!